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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive desmoplastic stromal
response. Fibroblast activation protein-α (FAP) is best known for its presence in stromal cancer-associated fibroblasts
(CAFs). Our aim was to assess whether FAP expression was associated with the prognosis of patients with PDAC
and to investigate how FAP expressing CAFs contribute to the progression of PDAC.
Methods: FAP expression was immunohistochemically assessed in 48 PDAC specimens. We also generated a
fibroblastic cell line stably expressing FAP, and examined the effect of FAP-expressing fibroblasts on invasiveness
and the cell cycle in MiaPaCa-2 cells (a pancreatic cancer cell line).
Results: Stromal FAP expression was detected in 98 % (47/48) of the specimens of PDAC, with the intensity being
weak in 16, moderate in 19, and strong in 12 specimens, but was not detected in the 3 control noncancerous
pancreatic specimens. Patients with moderate or strong FAP expression had significantly lower cumulative survival
rates than those with negative or weak FAP expression (mean survival time; 352 vs. 497 days, P = 0.006). Multivariate
analysis identified moderate to strong expression of FAP as one of the factors associated with the prognosis in
patients with PDAC. The intensity of stromal FAP expression was also positively correlated to the histological
differentiation of PDAC (P < 0.05). FAP-expressing fibroblasts promoted the invasiveness of MiaPaCa-2 cells more
intensively than fibroblasts not expressing FAP. Coculture with FAP-expressing fibroblasts significantly activated cell
cycle shift in MiaPaCa-2 cells compared to coculture with fibroblasts not expressing FAP. Furthermore, coculture
with FAP expressing fibroblasts inactivated retinoblastoma (Rb) protein, an inhibitor of cell cycle progression, in
MiaPaCa-2 cells by promoting phosphorylation of Rb.
Conclusions: The present in vitro results and the association of FAP expression with clinical outcomes provide us
with a better understanding of the effect of FAP-expressing CAFs on the progression of PDAC.
Background
Pancreatic ductal adenocarcinoma (PDAC) is character-
ized by an aggressive course, early metastasis, and a
limited response to chemotherapy and radiotherapy,
resulting in the overall 5-year survival rate of less than
5 % [1–4]. In many solid tumors, the stroma is increas-
ingly recognized to be important in promoting tumor
proliferation, invasion, metastasis, and chemoresistance
[5]. PDAC is also characterized by an extensive
desmoplastic stromal response. Cancer-associated fibro-
blasts (CAFs) are currently recognized to be fibroblasts
that acquire an activated phenotype within the tumor
stroma [6]. Mounting evidence suggests that CAFs
actively communicate with and stimulate tumor cells,
thereby contributing tumor development and pro-
gression [6–8].
Fibroblast activation protein-α (FAP) is a 95-kDa cell
surface glycoprotein belonging to the serine protease
family that cleaves the peptide bound between proline
and other amino acids, and this activity modifies various
bioactive molecules [9]. Homodimerization to a 170-kDa
form is necessary for the dipeptidyl peptidase and
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gelatinase activities [10]. FAP is best known for its pres-
ence in stromal CAFs, found in over 90 % of epithelial
tumors [11, 12], even though it is also expressed in
reactive fibroblasts during embryonic development,
wound healing, chronic inflammation and in cancer cells
[13–16]. Recent studies have demonstrated that FAP
expressed in stromal CAFs has a critical role in the
clinical outcomes of patients with PDAC [12, 16]. In
addition, some biological properties of FAP such as
matrix production supportive for cell motility, immune
suppression, and angiogenesis during the extensive des-
moplastic response associated with this cancer have been
demonstrated [17–20]. However, it remains to be eluci-
dated how FAP-expressing CAFs contribute to the dis-
ease progression of PDAC. The aim of this study was to
assess the relation of FAP expression in CAFs to overall
survival in patients with PDAC and to investigate the




PDAC specimens were obtained from 48 patients who
had undergone surgical resection for PDAC at Kawasaki
Medical School Hospital from 2006 to 2012. The study
protocol conformed to the 1975 Helsinki declaration,
and was approved by the Research Ethics Committee of
Kawasaki Medical School (Admission No: 894-1). The
need for informed consent was waived by the Research
Ethics Committee, because the study was retrospective
and some patients had already been dead. Three
resected noncancerous pancreatic specimens were used
as controls (one chronic pancreatitis tissue and two nor-
mal pancreatic tissues that were resected due to bile
duct cancer and duodenal papillary cancer). The clinical
characteristics of the patients were as follows: age,
71.5 ± 1.3; gender, 28 males (58 %); clinical stage of
PDAC based on the TNM classification of the Union
for International Cancer Control, 7 in stage I, 16 in
stage II, 16 in stage III, and 9 in stage IV. Alcohol
intake was defined as 37.5 g/day or more on the
basis of alcohol intake and pancreatic cancer risk de-
duced from a meta-analysis of the dose-risk relation
[21]. None of the patients underwent preoperative
chemotherapy, but 37 patients underwent postopera-
tive chemotherapy. All patients were followed up
after operation and survival time was defined as the
interval between the diagnosis of PDAC and death or the
last visit to the outpatient clinic up to March 31, in 2013.
Immunohistochemistry
The FAP-positive cells in paraffin-embedded specimens
were identified by immunohistochemical staining using
a rabbit anti-human Fibroblast activation protein, alpha
antibody (ab53066) (Abcam, Cambridge, MA), as de-
scribed previously [12].
Cell culture
MiaPaCa-2 and BxPC-3 pancreatic tumor cells and
NIH-3 T3 fibroblasts were obtained from DS Pharma
Biomedical (Osaka, Japan). MiaPaCa-2 and NIH-3 T3
were cultured in DMEM, and BxPC-3 in RPMI 1640, at
37 °C in a humidified atmosphere with 5 % CO2. Both
media contained 10 % fetal bovine serum (FBS).
Cloning of human fap gene and cell transfection
The human fap (hfap) gene was amplified by polymerase
chain reaction (PCR) using BxPC-3 genome as a tem-
plate and specific hfap primers that were deduced from
the NCBI reference sequence (NM_004460.3): fw_5’-
AGATCTATGAAGACTTGGGTAAAAATCGTA-3’ and
rev_5’-AGATCTTTAGTCTGGTCTACAAAGAGAAAA
CACTG-3’ (the incorporated BglII sites are underlined).
The resulting PCR products were cloned into the vector
pUC13, purified, sequenced, digested at the BglII site,
and subcloned in the pIRESneo3 (Clontech, Mountain
View, CA) vector. NIH-3 T3 cells were transfected with
the pIRESneo3 vector containing the hFAP cDNA or
pIRESneo3 vector using FuGENE® 6 Transfection Reagent
(Roche Applied Science, Mannheim, Germany) according
to the manufacturer’s instructions, followed by selection
with 400 μg/mL G418.
Invasion assay
Migration of MiaPaCa-2 cells was examined by the two-
chamber assay using a CultureCoat® 24 Well High BME
Cell Invasion Assay (Trevigen, Gaithersburg, MD), as
described previously [22]. Briefly, NIH-3 T3 fibroblasts
with/without FAP expression (5×104 cells/well) were
seeded into 24-well plates. MiaPaCa-2 pancreatic cancer
cells (5×104 cells/well) were seeded into culture inserts
(8 μm pores) and placed on 24-well plates containing
NIH-3 T3 fibroblasts. Both types of cells were cultured
in DMEM supplemented with 10 % FBS. After 24-h in-
cubation, the cell suspension in the upper chamber was
aspirated and the upper surface of the polycarbonate
membrane was carefully cleaned with cotton plugs. Cells
that migrated through the membrane were put on a
glass slide, stained, and counted in 4 randomly selected
fields/well in 4 wells at x100 magnification. The polycar-
bonate membrane is coated with a thick basement mem-
brane that is intended for use highly invasive cell lines.
In vitro coculture system
Using the same culture plates and culture inserts as
those used in invasion assay, MiaPaCa-2 cells (1×105
cells/well) were seeded in 6-well culture plates (Becton
Dickinson, Franklin Lakes, NJ). NIH-3 T3 fibroblasts
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with/without FAP expression (1×105 cells/well) were
seeded into the culture inserts (8 μm pores) and placed
on 6-well culture plates containing MiaPaCa-2 cells.
Both cell types were cultured in DMEM supplemented
with 10 % FBS.
Cell cycle analysis
After 24-h in vitro coculture, MiaPaCa-2 cells were fixed
with formalin, incubated for 30 min with DNA Dye
(Hoechst 33342), and rinsed with PBS. Plates containing
the cells were scanned with the ImageXpress Micro
Screening System (Molecular Devices, Tokyo, Japan).
Classification of cell phases was based on the fluores-
cence intensity of DNA dye. For cell number and cell
cycle analyses, the intensity of the integrated DNA
dye was assessed using the cell-cycle application
module (MetaXpress, Molecular Devices), as described
previously [23].
Western blotting
Cell lysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. The proteins were
transferred to polyvinylidene difluoride membranes (Pall
Corporation, New York, NY), blocked overnight at 4 °C
with 5 % skim milk and 0.1 % Tween 20 in Tris-buffered
saline, and subsequently incubated for 2-h at room
temperature with a mouse monoclonal antibody raised
against a partial recombinant FAP (Abnova, Taipei,
Taiwan), a rabbit anti-human Phospho-Rb (Ser807/811)
antibody (Cell Signaling Technology, Danvers, MA) and
mouse monoclonal anti-α-tubulin antibody (Sigma-
Aldrich, St. Louis, MO).
Statistical analysis
Continuous variables were expressed as mean ± SD.
Comparison between groups were performed using the
χ2 test for categorical variables. Cumulative survival was
calculated using the Kaplan-Meier method and the
differences among the groups were analyzed with the
log-rank test. Univariate and multivariate analyses of
predictors of survival were assessed using the Cox pro-
portional hazards model. A P value of less than 0.05 was
considered to be significant. All analyses described above
were performed using SPSS software (version 11, SPSS
Inc., Chicago, IL).
Results
Stromal FAP expression in resected PDAC
The expression of FAP was found predominantly in stro-
mal cells and slightly in cancer cells in resected PDAC
tissues. In the present study we focused on stromal FAP
expression in terms of the effect of stromal FAP expres-
sion on pancreatic cancer cells, and regarded FAP ex-
pressing stromal fibroblasts as CAFs. Stromal FAP
expression was exclusively found in fibroblasts and
graded by the number of positive cells per 1000 stromal
fibroblasts for three randomly selected views (negative,
weak < 350, 350 ≤moderate < 650, and 650 ≤ strong), as
shown in Fig. 1A. Stromal FAP expression was detected
in 98 % (47/48) of the specimens of PDAC, with the in-
tensity being weak in 16, moderate in 19, and strong in
12 specimens, but was not detected in the 3 control
specimens. Patients with moderate or strong FAP ex-
pression had significantly lower cumulative survival rates
than those with negative or weak FAP expression (mean
survival time; 352 vs. 497 days, P = 0.006) (Fig. 1B).
Multivariate analysis identified moderate to strong stro-
mal FAP expression, distant metastasis and alcohol in-
take as significant factors associated with overall survival
in patients with PDAC (Table 1). The intensity of stro-
mal FAP expression was also significantly correlated to
the histological differentiation of PDAC (Table 2).
Effect of FAP-expressing fibroblasts on invasiveness of
MiaPaCa-2 cells
To investigate the mechanism by which stromal FAP ex-
pression promoted the progression of PDAC, we estab-
lished NIH-3 T3 cells that stably expressed human FAP
(Fig. 2a). Increased invasiveness is one of the features
that support the rapid progression of PDAC. We then
examined effect of FAP-expressing fibroblasts on the in-
vasiveness of MiaPaCa-2 cells using an invasion assay in
a coculture system. The number of MiaPaCa-2 cells that
migrated through the polycarbonate membrane was
significantly greater in coculture with FAP-expressing
NIH-3 T3 cells than in coculture with NIH-3 T3 cells
not expressing FAP (Fig. 2b). There was no direct con-
tact between cells in culture plates and cells in culture
inserts. Thus, indirect coculture with FAP-expressing
NIH-3 T3 cells promoted the invasiveness of MiaPaCa-2
cells more intensively than that with NIH-3 T3 cells
not expressing FAP. These results suggested that
FAP-expressing fibroblasts promoted the invasiveness
of pancreatic cancer cells and were consistent with
the epithelial-mesenchymal transition promoted by
pancreatic stellate cells [21] and the increased inva-
sive velocity of FAP-overexpressing fibroblasts [17] in
previous reports.
Effect of FAP-expressing fibroblasts on cell cycle of
MiaPaCa-2 cells
The significant correlation between stromal FAP ex-
pression and histological differentiation of PDAC
prompted us to investigate whether stromal FAP ex-
pression affected the cell cycle of pancreatic cancer
cells. MiaPaCa-2 cells, which were cocultured with
NIH-3 T3 cells with/without FAP expression, were
examined for cell cycle distribution by using the integrated
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fluorescence intensity which reflected the cellular DNA
content (Fig. 3a). Coculture with FAP-expressing
NIH-3 T3 cells significantly decreased the fraction of
cells in the G0/G1 phase in MiaPaCa-2 cells com-
pared with coculture with NIH-3 T3 cells not expressing
FAP (Fig. 3b). These results suggested that coculture with
FAP expressing NIH-3 T3 cells activated switching from
G0/G1 to S/G2/M in MiaPaCa-2 cells.
Inactivation of retinoblastoma (Rb) by FAP-expressing
fibroblasts
Rb protein is an inhibitor of cell cycle progression, that
is, Rb arrests cells in G1 phase. Rb is phosphorylated
and dephosphorylated during the cell cycle; the hyper-
phosphorylated form predominates in proliferating cells,
whereas the hypophosphorylated form is generally more
abundant in quiescent or differentiating cells. Rb binds
to a gene regulatory protein called E2F and blocks the
transcription of S-phase genes. Phosphorylated Rb re-
duces its affinity for E2F, and then dissociates, allowing
E2F to activate S-phase gene expression [24]. Therefore,
we next examined the phosphorylation of Rb to clarify
the mechanisms underlying switching from G0/G1 to
S/G2/M in MiaPaCa-2 cells cocultured with FAP-ex-
pressing NIH-3 T3 cells. MiaPaCa-2 cells cocultured with
FAP-expressing NIH-3 T3 cells showed significantly
Fig. 1 Stromal fibroblast activation protein-α (FAP) expression in resected pancreatic ductal adenocarcinoma (PDAC), and relationship between intensity
of FAP expression and cumulative survival in patients with PDAC. A The expression of FAP was found predominantly in stromal cells and slightly in cancer
cells (a-c, x200 field magnification). Stromal fibroblast FAP expression was graded by the number of positive cells per 1000 stromal fibroblasts for three
randomly selected views (weak < 350 [d], 350≤moderate < 650 [e], and 650≤ strong [f]), but negative in chronic pancreatitis (g) and noncancerous
pancreatic tissues that were resected due to bile duct cancer (h) and duodenal papillary cancer (i) (d-i, x400 field magnification). B Cumulative survival
curves for PDAC patients with negative or weak FAP expression and those with moderate or strong FAP expression. The solid line and broken lines
indicate patients with negative or weak FAP expression and those with moderate or strong FAP expression, respectively. Log-rank test P = 0.006
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increased phosphorylation of Rb compared to those cocul-
tured with NIH-3 T3 cells not expressing FAP (Fig. 4).
These results suggested that coculture with FAP-
expressing NIH-3 T3 cells promoted phosphorylation
of Rb and subsequently activated the cell cycle shift
from G0/G1 to S/G2/M in MiaPaCa-2 cells.
Discussion
In the present study moderate to strong stromal FAP
expression, distant metastasis and alcohol intake was
identified as significant factors associated with overall
survival in patients with PDAC. These results are in part
untypical in terms of no correlation for post-operative
chemotherapy, tumor size, lymph node involvement, but
for alcohol intake. Heavy alcohol intake (≥37.5 g/day)
and relatively low proportion (18.7 %) of T1/T2 stage
tumors in our study population might be related to these
untypical results, even though the precise explanation
remains elusive. In addition, it needs to be careful for in-
terpretation of the results that the intensity of stromal
FAP expression was significantly correlated to the histo-
logical differentiation of PDAC, because the majority of
cases in both FAP expression and histological differenti-
ation of PDAC are not well differentiated. Therefore,
while FAP expression may play a role in determining
Table 1 Factors associated with overall survival in operated patients with PDAC
Univariate analysis Multivariate analysis








T3 or T4b 0.513
N1b 0.115
M1b 2.863 1.072-7.646 0.036 2.972 1.097-8.055 0.032





FAP moderate/strong 2.540 1.273-5.068 0.008 2.534 1.267-5.068 0.009
apostoperative, bTNM classification of Union for International Cancer Control (UICC), cclinical stage of PDAC by UICC, 1lymph duct invasion, 2vascular invasion,
3nerve invasion

























aTNM classification of the UICC, bUICC, Union for International Cancer Control
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histological differentiation, it does not seem to be the
dominant factor for determining histological differen-
tiation. It has been reported that FAP is expressed
exclusively in stromal fibroblasts of epithelial cancers
[12, 25–27], though some reports have suggested that
FAP is expressed in both the stromal and epithelial
compartments of cancers [16, 28–30]. Although this
issue is still controversial, we successfully amplified
the hFAP cDNA by PCR using BxPC-3 (a pancreatic
cancer cell line) mRNA as a template and specific
hfap primers, and established NIH-3 T3 cells that
stably expressed human FAP. The reason we used
BxPC-3 mRNA as the template for amplifying hfap
was the immunoblotting detection of FAP in BxPC-3 cells
in a previous study [16]. TGF-β is a powerful factor for in-
ducing FAP expression in NIH-3 T3 fibroblasts [31] and,
therefore, induction of FAP expression by TGF-β may be
more suitable in terms of mimicking the environment of
the stromal response to cancer in human PDAC tissue.
However, we chose to establish fibroblasts stably express-
ing FAP to avoid fluctuation in the expression level of FAP
under our experimental conditions. The use of cells of
different species (NIH-3 T3 cells generated from embry-
onic mouse fibroblasts and MiaPaCa-2 cells from human
pancreatic cancer) may not be a confounding factor,
because human FAP, not mouse FAP, was expressed in
NIH-3 T3 cells.
The present findings that stromal FAP expression in
resected PDAC specimens was negatively correlated with
patients’ overall survival was consistent with the associ-
ation of higher FAP expression with worse clinical
outcomes in patients with PDAC in previous studies
[12, 16]. We identified at least two mechanisms that
accounted for these results. One was the effect of FAP on
the invasiveness of pancreatic cancer cells. FAP-expressing
NIH-3 T3 cells promoted the invasiveness of MiaPaCa-2
Fig. 2 Effect of fibroblast activation protein-α (FAP) expressing NIH-3 T3 cells on invasiveness of MiaPaCa-2 cells. a Western blot analysis shows
stable expression of FAP in NIH-3 T3 cells. b MiaPaCa-2 cells that were cocultured with NIH-3 T3 cells with/without FAP expression and then
migrated through the polycarbonate membrane were stained with H&E, and counted in 4 randomly selected fields/well in 4 wells at x100 field
magnification. The invasion assay was performed 13 times. *, P < 0.01
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Fig. 3 Cell cycle analysis of MiaPaCa-2 cells after coculture with NIH-3 T3 cells with/without FAP expression. a MiaPaCa-2 cells that were cocultured
with NIH-3 T3 cells with/without FAP expression were examined for cell cycle distribution by using the integrated fluorescence intensity, which reflects
cellular DNA content with the ImageXpress Micro Screening System. b Cell cycle distribution in MiaPaCa-2 cells that were cocultured with NIH 3 T3 cells
with/without FAP. The experiments were repeated four times. Dark gray bars and bright gray bars indicate the G0/G1 phase fraction and S/G2/M phase
fraction, respectively. *, P < 0.05
Fig. 4 Phosphorylation of Rb protein in MiaPaCa-2 cells that were cocultured with NIH-3 T3 cells with/without FAP. a Immunoblots for phosphorylated
Rb (P-Rb) using MiaPaCa-2 cell lysates that were cocultured with NIH 3 T3 cells with/without FAP. b The P-Rb expression level was normalized to that of
tubulin. The experiments were repeated three times. The black and gray bars indicate MiaPaCa-2 cells after coculture with FAP-expressing NIH-3 T3 cells
and MiaPaCa-2 cells after coculture with NIH-3 T3 cells without FAP expression, respectively. *, P < 0.05
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cells more intensively than NIH-3 T3 cells not expressing
FAP without direct contact between cells. Antiplasmin-
cleaving enzyme (APCE) has been identified as a soluble
form of FAP, resulting from cleavage of the Cys23-Ile24
bond in the transmembrane or extracellar domain [32].
Therefore, it is reasoned that FAP-expressing fibroblasts
promoted the invasiveness of MiaPaCa-2 cells even in the
absence of direct contact of these two cells, even though
we could not measured the APCE level in culture medium.
The extracellular matrix is composed of glycoproteins,
collagen, and proteases that modify structural proteins and
regulate clotting factors that can facilitate pancreatic can-
cer cell invasion [33]. FAP-overexpressing fibroblasts have
been shown to produce an extracellular matrix that en-
hances the invasive velocity and directionality of pancreatic
cancer cells [17]. In addition, pancreatic stellate cells ob-
tained from the resected pancreatic tissues of patients with
pancreatic cancer have been shown to increase the migra-
tion of pancreatic cancer cells in coculture system [22].
These results are well consistent with the increased inva-
siveness of MiaPaCa-2 cells in coculture with FAP-
expressing NIH-3 T3 cells in this study.
The other mechanism is the activation of cell cycle
progression by FAP-expressing fibroblasts. To our know-
ledge, this is the first report to demonstrate that FAP-
expressing fibroblasts promote phosphorylation of Rb
and subsequently activate cell cycle progression in pan-
creatic cancer cells. When cells are stimulated to divide
by extracellular signals, active G1-cyclin-dependent pro-
tein kinase (Cdk) accumulates and phosphorylates Rb,
reducing its affinity for E2F. Therefore, further studies
including assessment of the effect of FAP on G1-Cdk
expression/activity are required to clarify how FAP-
expressing fibroblasts activate phosphorylation of Rb
protein in pancreatic cancer cells. The activated cell
cycle shift from G0/G1 to S/G2/M in pancreatic cancer
cells cocultured with FAP-expressing fibroblasts may be
one of the important mechanisms underlying the signifi-
cant correlation between the intensity of stromal FAP
expression and the histological differentiation of cancer
cells in patients with PDAC (Table 2). On the other
hand, FAP expression has been reported in mesenchy-
mal stem cells [34, 35]. Mesenchymal stem cells within
tumor stroma have been shown to promote tumor
growth and metastatic capacity of cancer cells [36, 37].
These results seem to provide an interesting link be-
tween FAP expression and the differentiation state of
PDAC. Albeit with data from only one cell line, our in
vitro results and the association of FAP expression with
clinical outcomes provides us with a better understand-
ing of the influence of FAP-expressing CAFs on epithe-
lial tumor cell behavior and targeted therapeutics aimed
at disrupting specific tumor-stromal interactions. In
addition to the activation of invasiveness and/or cell
cycle progression, FAP-expressing fibroblasts have a role
in immune suppression [18] and angiogenesis during the
extensive desmoplastic response associated with this
cancer [19, 20]. Thus, FAP-expressing fibroblasts are
critical for remodeling a permissive stromal environment
that supports pancreatic cancer progression.
Conclusion
Moderate to strong expression of FAP was one of the
factors associated with the prognosis in patients with
PDAC and the intensity of stromal FAP expression was
positively correlated to the histological differentiation of
PDAC. As the mechanisms underlying these clinical re-
sults, FAP-expressing fibroblasts promoted the invasive-
ness and activated cell cycle of a pancreatic cancer cell
line in vitro.
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